Guide

Form FDA 483 for clinical investigators

A Form FDA 483 — “Inspectional Observations” — is the document an FDA inspector issues at the close of an inspection when they have observed conditions that, in their judgment, may constitute violations of the regulations. For a clinical investigator it is the first written account of what an inspection found. It is not a finding of violation, not a classification, and not a warning letter — three things it is routinely mistaken for.

What a 483 is

The inspector writes the 483 on site, from their own observations, and presents and discusses it with the clinical investigator at the closing meeting. Each numbered observation describes a specific condition the inspector saw — consent forms signed after procedures began, case histories that do not support the case report forms, investigational drug records that do not reconcile, tasks delegated to staff the investigator did not supervise. The observations are the inspector’s; they are not yet FDA’s position. A 483 states on its face that the observations do not represent a final agency determination.

What happens next

The response. The clinical investigator may respond in writing. FDA’s practice is to consider a response received within 15 business days before deciding what action, if any, to take. A thorough response with corrective actions can affect the classification and what follows.

The classification. The reviewing center evaluates the inspection report, the 483 and the response, and classifies the inspection NAI, VAI or OAI. This is FDA’s decision about the observations, made afterward — an inspection can end with a 483 and be classified NAI.

Further action, sometimes. An OAI can lead to a warning letter, an untitled letter, or — for repeated or deliberate violations — a NIDPOE letter opening disqualification. Most 483s lead to none of these.

The whole sequence, with how long each step takes and who is told: what happens after a BIMO inspection.

483 vs. classification vs. warning letter

Form FDA 483. Issued on site by the inspector at the close of the inspection. Observations, not determinations. Goes to the clinical investigator.

Classification (NAI / VAI / OAI). Assigned by the center after review, weeks to months after the inspection. FDA’s summary judgment of the inspection.

Warning letter. Issued by the center, generally after an OAI classification. FDA’s formal position that violations occurred, with a request for a response. Goes to the clinical investigator.

What a sponsor can learn from a site’s 483 — and how

FDA sends inspection findings to the clinical investigator, not typically to the sponsor, so a 483 reaches a sponsor in one of two ways: the site shares it, or the sponsor asks. Neither is automatic. The investigator is not required to report the inspection to the sponsor unless a quality agreement says so, and a large site often runs several sponsors’ trials, so the inspection may have concerned another study. Asking is reasonable; a site that shares its 483 and its response is showing you how it handles findings, which is itself useful information.

What enters the FDA inspection record is the inspection with its classification and the findings FDA cited — the cited regulation and FDA’s own short description of each. Clinical Precedent assembles that record for each clinical investigator and site, and it is what clinical investigator vetting reads. The 483 itself adds the inspector’s narrative detail; the cited findings tell you what FDA decided was worth recording.

Reading a 483 when selecting a site

Count and severity both matter, and the response matters more than either. Four observations about consent timing at one site and four about investigational-drug reconciliation at another are different risks for different protocols. A site whose responses and corrective action plans addressed each observation, and whose next inspection was NAI, has demonstrated something a site with no inspection history has not. Where the observations touch the protocol’s own risks, the options are the usual three: ask for the responses and corrective action plans, visit the site before signing, or choose a site without this history.

Questions this page answers

What is a Form FDA 483?

It is the list of observations an FDA inspector issues at the close of an inspection when they have observed conditions that may constitute violations of the regulations. It is presented to the clinical investigator at the closing meeting. The observations are the inspector’s and do not represent a final agency determination.

Is a Form FDA 483 the same as a warning letter?

No. The 483 is issued on site by the inspector and lists observations. A warning letter is issued later by the reviewing center, generally after an OAI classification, and states FDA’s formal position that violations occurred. Most 483s do not lead to a warning letter.

How long does a clinical investigator have to respond to a 483?

FDA’s practice is to consider a written response received within 15 business days before deciding on further action. A response is not mandatory, but submitting a response shows FDA that the inspection findings are being taken seriously, and a thorough one with corrective actions can affect the classification and whether a warning letter follows.

Does a 483 mean the inspection was classified OAI?

No. The classification is assigned afterward by the center, after reviewing the report, the 483 and the response. An inspection can end with a 483 and be classified NAI or VAI; OAI is the least common classification.

Does the sponsor receive a copy of a clinical investigator's 483?

Not from FDA, as a rule; FDA sends inspection findings to the clinical investigator. A sponsor usually sees a 483 only if the site shares it, often because the sponsor asked. The classification and the findings FDA cited become part of FDA’s inspection record, which Clinical Precedent assembles into one record per clinical investigator, site, CRO and IRB.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.